Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is...
-
STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is...
-
STOCKHOLM, September 5, 2018. Karolinska Development's portfolio company Forendo Pharma announces today that Vesalius Biocapital III Partners (Vesalius) joins Forendo Pharma's existing international...
-
STOCKHOLM, September 5, 2018. Karolinska Development's portfolio company Forendo Pharma announces today that Vesalius Biocapital III Partners (Vesalius) joins Forendo Pharma's existing international...
-
STOCKHOLM - den 16 augusti 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari - juni 2018. Den fulla rapporten är tillgänglig på bolagets...
-
STOCKHOLM - 16 August 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report for the period January - June 2018. The full report is available on the Company's...
-
STOCKHOLM, 13 juli 2018. Karolinska Development (Nasdaq Stockholm: KDEV) meddelar att HealthCap investerar 60 mkr och blir en ny aktieägare i Modus Therapeutics. I samband därmed sker en...
-
STOCKHOLM, July 13, 2018. Karolinska Development (Nasdaq Stockholm: KDEV) announces that HealthCap with an investment of SEK 60 million becomes a new shareholder of Modus Therapeutics. At the same...
-
STOCKHOLM, July 4, 2018. Karolinska Development's portfolio company Forendo Pharma today announces that it has received clinical trial authorization (CTA) from the Medicines and Healthcare products...
-
STOCKHOLM, July 4, 2018. Karolinska Development's portfolio company Forendo Pharma today announces that it has received clinical trial authorization (CTA) from the Medicines and Healthcare products...